ARTICLES

 

Estrogens and breast cancer

 

SUSAN E. HANKINSON, R.N., SC.D.,(1) MEIR J. STAMPFER, M.D., Dr. P.H.(2)

 

 

ABSTRACT
In this review, we summarize the epidemiologic evidence for the associations of oral contraceptives and postmenopausal hormones with risk of breast cancer. We also describe the biologic plausibility of these relationships. Overall, there appears to be little, if any, increase in risk with oral contraceptive use in general, even among users for 10 or more years. However, compared to never users, current oral contraceptive users appear to have a modest elevation in risk that subsides within about 10 years after cessation of use. For postmenopausal hormones, the weight of the evidence suggests little or no increase in risk among users of short duration, or for use in the past. However, current longer term use is associated with an increased risk of breast cancer that increases with duration. This increase in risk is large enough, and well enough supported, to be considered along with the other risks and benefits of postmenopausal hormone therapy.
KEY WORDS: breast neoplasms; estrogens; menopause; review

 

RESUMEN
Se presenta una revisión de la evidencia epidemiológica para la asociación de consumo de anticonceptivos orales y hormonas de suplementación hormonal en la posmenopausia, y el riesgo de cáncer de mama (CM). Se discute también la plausibilidad biológica de esta posible relación. Se hace énfasis, en la escasa evidencia, si existe, del incremento de riesgo de cáncer de mama con el uso de anticonceptivos orales por un periodo mayor de 10 años. Sin embargo, comparando las mujeres que no tienen el antecedente de consumo de hormonales anticonceptivos, con las que si lo tienen, existe un leve incremento de riesgo de CM que persiste aún 10 años de haber suspendido la ingesta. Para mujeres que consumen suplementos de reemplazo hormonal en la posmenopausia, existe un escaso o nulo incremento en el riesgo de CM, entre usuarias de corta duración, o de uso en el pasado. Mujeres con antecedentes de consumo de hormonales de reemplazo incrementan el riesgo de CM, el cual se incrementa con la duración. Por esta razón es pertinente considerar los riesgos y beneficios de la terapia hormonal en la etapa posmenopáusica, discutidos en este documento.
PALABRAS CLAVE: neoplasmas de la mama; estrógenos; menopausia; revisión

 

 

Biologic plausibility of an association of hormones with breast cancer risk

Several lines of evidence support the hypothesis that exogenous estrogens play an important role in the etiology of breast cancer. Rates of breast cancer increase rapidly in the premenopausal years, but the rate of increase slows sharply at menopause, when endogenous estrogens decline rapidly (Figure 1). Several reproductive variables that alter estrogen status also affect risk of breast cancer (Table I). For example, early age at menarche, and late age at menopause (reflecting prolonged ovarian function and estrogen production) are associated with increased risk of breast cancer.5,6 During pregnancy, estrogen levels are markedly elevated, and this is associated with a temporary increase in breast cancer risk.3 The number of full-term pregnancies, and their timing, affect risk.7 In addition estrogens and progesterone promote mammary tumors in animals, and hormonal manipulations such as anti-estrogens (e.g., tamoxifen) are useful for treatment of breast cancer.

 

y043711.GIF (7393 bytes)

 

 

y043721.GIF (18187 bytes)

 

Women who have menopause before age 45 have approximately half the risk of breast cancer compared to women who become menopausal after age 55 years.3 In addition, after menopause, adipose tissue is the major source of estrogen and obese postmenopausal women have both higher levels of endogenous estrogen and a higher risk of breast cancer.8,9 These observations suggest that altering the postmenopausal hormonal milieu to approach that of premenopausal women may lead to a continued acceleration in the rate of breast cancer, as is observed in premenopausal women.

 

Oral contraceptives

Prevalence of oral contraceptive use

In 1988, over 10.7 million US women were currently using oral contraceptives.10 Most combined oral contraceptives contain ethinyl estradiol (or mestranol) and a progestin. The estrogen dose in OCs has ranged from more than 80 mcg in 1960 to 30 mcg, the dose most commonly used today; at least nine different progestins have been used.11,12 Patterns of use also have changed considerably over time with both increasing durations of use and a trend towards earlier ages at first use.

Epidemiologic findings

Generally, the results of epidemiologic studies have been quite reassuring in showing little if any increase in overall risk of breast cancer among ever users or users for extended durations. Several aspects of OC use, particularly long durations of use in young women or prior to a first pregnancy, have remained of concern. Recently, individual data from 54 epidemiologic studies were collected and analyzed centrally on oral contraceptive use and risk of breast cancer.13 In this large pooled analysis, data from 53 297 women with breast cancer and 100 239 women without breast cancer were evaluated. The findings are summarized below.

Any use of oral contraceptives

In the pooled analysis, ever use of OCs was associated with a very modest increase in risk (RR= 1.07; 95% CI 1.04-1.11). Although this finding of only a very small increase in risk is reassuring, defining OC use this way is misleading because women in the "ever" use category include women with long and short-term use, so that any true relationship with one particular aspect of OC use may be missed.

Duration of use

Overall. Most studies have observed no significant increase in breast cancer risk with long durations of use (³ 5 years). In one meta-analysis where results from 10 studies were combined, the relative risk associated with 10 or more years of use was 1.14 (95% CI= 0.90-1.42).14 In a second meta-analysis, the relative risk was 1.1 for greater than five years of use when results were combined for either nine case-control studies (95% CI= 0.9-1.2) or four cohort studies (95% CI= 0.9-1.4).15 These results were from analyses where women of all ages were combined and provide considerable evidence against any material adverse effect of long-term OC use overall. Similar findings have generally been observed when long-term use was evaluated among either postmenopausal women or women over the age of 45 years.

Duration of use among young women. In several studies16-19 an elevated relative risk was observed among young women (generally less that 45 years) who used OCs for extended durations. In two meta-analyses, summary relative risks for long durations of use in young women were 1.514 and 1.4 (95% CI= 1.3-1.6).15 The greatest increase tended to be observed in the youngest women, generally women less than 35 years of age;18-20 this observation also was noted in several more recent case-control studies.21-23

Several cohort studies also have evaluated these relationships.24-27 In the Oxford Family Planning Association study, over 17 000 women ages 25-39 years were followed for up to 19 years.24 No association was observed with increasing duration of use among women 25-44 years, although only 14 cases were <35 years of age. In the Royal College of General Practitioners cohort, 23 000 women who used OCs and 23 000 non-users were enrolled in 1968 and followed to 1985.25 Although little if any increase in risk was noted with increasing duration of use overall, a substantial increased risk was observed among women ages 30-34 years (e.g., relative risk of 10.2 for OC use of 10+ years relative to never use). However, these results must be interpreted cautiously as only 24 cases of breast cancer occurred among women 30-34 years, the follow-up rate in this cohort was low (as of 1985, less than 60% of the total possible number of person-years of follow-up was accounted for) and the incidence rate among the 30 to 34 year old women who did not use OCs was considerably lower than the age-specific national breast cancer rates. The largest prospective study of this association was the Nurses’ Health Study cohort. 121 700 women were enrolled in 1976 and have been followed every two years since that time. The follow-up rate in this cohort has been consistently 90% or higher. From 1976 to 1992 (during which time 3383 breast cancers were confirmed), no significant association was noted between duration of use and breast cancer risk either over, or among premenopausal women or women over 35 years of age.26-27 Similarly, in the pooled analysis, no substantial increase in risk with long-term OC use was noted among women 30 years of age and older.

Use before a first full-term pregnancy

Any influence of OCs on the breast was hypothesized to be greatest prior to the cellular differentiation that occurs with a full-term pregnancy.28 In two meta-analyses, the summary relative risk indicated a modest increase in risk with long-term use (RR= 1.7;14 RR= 1.415). However, results of the individual studies tended to vary substantially and in few of the studies was a relation noted between exposure duration and disease risk. Additionally, in several more recent studies,21,22,29 and in the large Nurses’ Health Study cohort,26,27 no increase in risk was observed specifically in relation to use prior to a first pregnancy.

Recency of use

Few studies have specifically evaluated the relationship between current or very recent use of OCs and breast cancer risk, but they generally have noted at least a modest increased risk16,19,22,26 relative to never users, suggesting that OCs may act as late stage promoters. In the Nurses’ Health Study cohort, current users had a 50% higher risk than never users.26 This increased risk was not attributable to increased disease detection among current OC users.

In the pooled analysis, current and recent users of oral contraceptives had an increased risk of breast cancer (RR for current vs never users= 1.24; 95% CI= 1.16-1.34) which subsided within 10 years of stopping OC use13 (Figure 2). Importantly, the authors observed a modest increased risk of breast cancer only among current and recent OC users, and did not observe any independent effect of long durations of use on risk of breast cancer even among very young women. Thus, the increased risk of breast cancer observed among young (<35 yrs), long-term OC users in past individual studies was possibly due to recency of OC use rather than duration of use.

 

y043731.GIF (14288 bytes)

 

Type and dose of OC

Although the specific formulation of the OC might be important in determining cancer risk, studies of this issue are difficult because study participants may not be able to remember specific formulations; very large studies are needed to have enough statistical power to examine individual brands and, finally, no satisfactory classification system exists to categorize specific OC formulations by their effect on breast tissue. For these reasons, few studies have evaluated specific OC formulations in relation to breast cancer risk. The pooled analysis found no significant variation in risk between the specific types of OCs or with dose.13

Progestin-only contraceptives

These contraceptives include progestin-only pills ("mini-pill"), depot-medroxyprogesterone (DMPA) and implantable levonorgestrel (Norplant). Although the progestin-only pill has been evaluated in few studies, to date, no increase in breast cancer risk has been observed for ever users18,30-33 and, in the two studies where duration of use was evaluated18,33 longer term users were observed to have either a similar or lower risk of breast cancer compared to never users.

In the most comprehensive of DMPA,34 no significant increase in risk was observed with increasing duration of use, although both long-term users who began use before age 25, and users under age 35 overall were observed to have a modest increase in breast cancer risk. Norplant, a long-acting contraceptive which is implanted sub-dermally, was introduced in the United States in 1990. No epidemiologic data have been published on Norplant’s influence, if any, on breast cancer risk.

Summary

Results of epidemiologic studies have provided considerable reassurance that there is little, if any, increase in risk with OC use in general, even among women who used OC for 10 or more years. Accumulating data also suggest that long-term OC use prior to a first full-term pregnancy does not appreciably increase risk.

The finding from case-control studies, of an increase in risk among young women who used OCs for extended durations has not been confirmed by the larger prospective studies. In the recent pooled analysis, (which included nearly all published studies) long-term use among young women was not independently associated with an increase in breast cancer risk. Rather current users and recent users (<10 years since last use) were observed to have a modest elevation in risk compared to never users. This relationship most likely could not be discerned from the individual studies, as duration of use, rather than regency of use, was often reported. Among young women, the long-term users are much more likely to be recent users such that a very large data set (such as the pooled analysis) was needed to determine the independent effect of these variables.

It is important to note that current and recent users, the group that appears to have a modest increase in risk, are generally young (<45 years) and thus have a low absolute risk of breast cancer. Hence, a modest increase in their risk will result in few additional cases of breast cancer. Nevertheless, this apparent increased risk among current and recent users should be factored into the overall decision whether or not to use OC.

 

Postmenopausal hormone use

Prevalence of postmenopausal hormone use

Postmenopausal estrogens have been used for over half a century. By the mid 1970’s almost 30 million prescriptions were being filled annually in the US35 Both the formulations prescribed, patterns of use and delivery systems have changed substantially over time.

Epidemiologic findings

Estrogen only

The possible relation between postmenopausal estrogen use and risk of breast cancer has been investigated in over three dozen epidemiologic studies over the past 20 years.36-40 Most of these studies have been summarized in six meta-analyses.36,41-45 A summary of these findings, plus a more detailed discussion of several of the most important and most recent studies is provided below.

Ever use. All of the meta-analyses have concluded that overall, ever users of postmenopausal estrogens have little or no increase in risk of breast cancer compared with women who have never used this therapy. Depending upon the inclusion criteria for the meta-analyses, the relative risk estimates across studies range from 1.01 to 1.07 with narrow confidence limits.

Duration of use. In a meta-analysis limited to case-control studies, Steinberg et al.42 reported a 30% increase in risk with more than five years of use (Table II), and a 45% increase in risk after 10 years of use when combining results from the follow-up studies.42 In another meta-analysis, Colditz et al.44 calculated a summary relative risk of 1.23 (95% confidence interval 1.08-1.40) for ten or more years of hormone use. Sillero-Arenas43 found the same overall estimate, but when stratified by menopause type, the relative risks were somewhat higher: for more than 12 years of use, among women with a natural menopause, the relative risk was 1.32 (1.08-1.40), and for those with a surgical menopause, 1.63 (95% CI: 1.26-2.12). Grady et al. also calculated a a relative risk of 1.25 (95% CI:1.04-1.51) for eight or more years of use.36

 

y043751.GIF (24116 bytes)

 

Results of several large studies have become available since the publication of these meta-analyses. The largest of these, in terms of number of cases, was a population-based case-control study of 3,130 cases and 3 698 controls.37 In that study, Newcomb et al. observed no significant positive association between postmenopausal hormone use and breast cancer risk, even among long-term users. With ³ 15 years of estrogen use, the relative risk was 1.11 (95% CI: 0.87-1.43).

In another recent population-based case-control study, Stanford et al.46 observed no increase in risk regardless of duration of postmenopausal hormone use. Compared to never users, women using hormones for 12 to 14, 15 to 19 and ³ 20 years had relative risks of 1.0 (95% CI= 0.5-2.0), 0.5 (95% CI= 0.3-1.0) and 1.0 (95% CI= 0.5-2.0) respectively. However, as with the study by Newcomb et al., the 95% confidence intervals included the elevated relative risks observed in the meta-analyses.

One difficulty in interpreting the results of case-control studies is the impact of nonparticipation, particularly among the controls. For example, in the Stanford study, the response rate among controls was approximately 70%. In the general population, estrogen users tend to have a somewhat higher socio-economic status on average47 and, typically, better educated individuals are more likely to participate as controls in health-related research studies. Thus, if the responding controls were more likely to be estrogen users than the nonresponding controls, the observed relative risk may have been biased towards 1.0 (no effect). As any true increase in risk is likely to be small, even a modest bias in control participation could obscure the results.

Data from several recent cohort studies, also not included in the meta-analyses, are available. Initial results from the prospective Netherlands Cohort study of 62 573 women were recently reported.38 However, long-term use was uncommon, with only 14 cases in the category of five or more years of use. The relative risk in this category was 0.9 (95% CI= 0.4-2.1); these broad confidence intervals are clearly compatible with a wide range of true effects. Similar null findings with broad confidence intervals were observed among the small number of recent users.

Colditz et al. recently reported updated results from the Nurses’ Health Study.39 This is the largest prospective study conducted to date on this topic, with 725 550 person-years of follow-up among post-menopausal women, and 1 935 cases of newly diagnosed invasive breast cancer. In this analysis, because of the similar findings for estrogen and estrogen plus progestin use, results were presented for all hormone use combined. An excess risk of breast cancer was limited to women with current or very recent use of postmenopausal hormones. The risk increased with increasing duration of use, and was statistically significant among current users of five or more years duration (compared to never users: RR for 5-9 years of use= 1.36, 95% CI= 1.15-1.61; RR for ³ 10 years of use= 1.47, 95% CI= 1.22-1.76).

Recency of use. Data on recency of use are more sparse because many studies did not distinguish current from past users. The Sillero-Arenas meta-analysis calculated a relative risk for current use of 1.63 for women with natural menopause and 1.48 for women with surgical menopause. Colditz et al. estimated a summary relative risk of 1.40 (95% CI=1.20-1.63) comparing current to never users.

In the Newcomb study,37 recent long-term use (at least 5 years use within two years of the cases’ date of diagnosis) was not associated with an increased risk, with a relative risk of 0.91 (0.72-1.14). Similarly, in the Stanford study46 no significant associations between postmenopausal hormone use and breast cancer risk were noted regardless of recency of use (RR for current use vs never use= 0.9; 95% CI= 0.7-1.3). 

In the Nurses’ Health Study cohort,39 past users were not at increased risk regardless of duration of use. Among current users, only women with 5 or more years of use had a significantly increased risk of breast cancer (RR for 5-9 years of use= 1.36, 95% CI=1.15-1.61; RR for ³ 10 years of use= 1.47, 95% CI= 1.22-1.76 all compared to never users). In the Breast Cancer Detection Demonstration project cohort relative risks ranged from 1.0 to 1.4 among current users of 5 to ³ 15 years duration.48

Some investigators have suggested that the increased risk observed in many of the studies is an artifact of increased surveillance for breast cancer among women taking hormones. Consistent with such a possibility, both Colditz et al. and Schairer et al.48 reported a higher relative risk associated with in situ disease than invasive disease. However, in both of these studies a significant positive (although weaker) association was noted when only invasive breast cancer cases were considered. In addition, in the Nurses’ Health Study, mammography rates uniformly exceeded 90% even among women who never used hormones. Moreover, current hormone users of short duration did not have an elevated risk, despite slightly higher mammography rates than never users. Finally, higher breast cancer morbitity was observed among participants who were long-term current users at the time of diagnosis, further evidence that the association did not result simply from increased detection of early cancers among hormone users.

Type and dose of estrogen. Limited data are available regarding the effects of dose or type of estrogen on breast cancer risk. In the US, approximately three quarters of the hormone use has been conjugated equine estrogens, thus findings from most US studies represent use of conjugated estrogens only. Colditz et al.39 observed similar increases in breast cancer risk among current users of conjugated estrogen alone (RR= 1.32; 95% CI= 1.14-1.54), and other estrogen formulations (RR= 1.28; 95% CI= 0.97-1.71), all compared to never users. In the Swedish cohort, the relative risk of breast cancer appeared slightly higher among users of estradiol formulations than among women using conjugated estrogens although the estimates were imprecise.49 In a meta-analysis where published results from European (n= 3) and US studies (n= 9) were separately pooled,44 the relative risk for ever use was higher in Europe (1.31) than in the US (1.05) again suggesting that synthetic estrogens may confer a slightly higher breast cancer risk than use of conjugated estrogens. In several meta-analyses that examined the influence of dose on breast cancer risk (generally <1.25mg/day vs ³ 1.25 mg/day), no substantial variation in effect was observed41,44 although the relative risks observed for higher doses tended to vary from study to study.

Risk according to breast cancer risk factor profile. Several studies have evaluated the association between estrogen use and breast cancer risk within strata of other breast cancer risk factors, such as age, family history of breast cancer, adiposity, previous oral contraceptive use and alcohol intake. However, to date these analyses have generally been limited by the small number of participants in any one subgroup thus leading to the examination of ever versus never hormone use (instead of the preferred duration and recency of use) and to imprecise estimates of relative risk.

In one of the meta-analysis, the estrogen/breast cancer relationship did not vary substantially by family history of breast cancer (evaluated in 10 studies), benign breast disease (12 studies), and type of menopause or number of ovaries. In some39,50-52 but not all studies, a higher relative risk has been observed among older women. Although the findings have not been entirely consistent, at least six studies have reported a modestly stronger association between estrogen use and breast cancer among leaner women.39,46,52-54

Estrogen plus progestin use

The addition of a progestin to estrogen regimens has become increasingly common as it reduces or eliminates the increased risk of endometrial hyperplasia and cancer associated with using unopposed estrogens. In the US, by the mid-1980s, almost 30% of postmenopausal hormone prescriptions included a prescription for progestin.55

Two of the first studies to assess the impact of added progestin suggested that it could decrease breast cancer risk.56,57 However, these studies were small and potentially important confounders (e.g., age, parity) were not accounted for in the analysis. Since then, several additional studies have been published; taken together these studies indicate that a substantial protective effect of typical doses used in postmenopausal hormone therapy can be ruled out.39,49,52,58-60

Findings from these latter studies have not been consistent however. In several case-control studies58,59 but not others52,60 an increased risk with use of estrogen plus progestin was suggested. Neither of the two most recent case-control studies has observed a significant increase in risk with estrogen plus progestin use.37,46

Only two prospective studies have reported on this relationship and their findings were similar. Bergkvist et al. observed a relative risk of 4.4 (95% CI= 0.9-22.4) among women who used estrogen plus progestin for ³ 6 years compared to never users.49 Women using hormones for shorter duration did not appear at an increased risk (relative risks varied from 0.5 to 0.9) but confidence intervals were wide; the type of progestin not specified. Colditz et al. recently reported findings from the Nurses’ Health Study where, among women using progestins, about two-thirds used 10 mg of medroxyprogesterone.39 The relative risk associated with current estrogen plus progestin use was 1.4 (95% CI= 1.2-1.7), very similar to that for estrogen alone. Thus overall, although the recently published papers differed in their findings, within each study, no material difference in risk was observed comparing those who used estrogen alone and those using estrogen plus progestin.

Widespread use of estrogen plus progestin is so recent that few data are available to evaluate the effect of different formulations, doses or schedules of use on risk of breast cancer.

Summary of data on postmenopausal hormone use and breast cancer risk

Although aspects of the relationship between PMH and breast cancer risk remain unresolved, several areas of agreement have emerged. The finding of no increase in risk comparing ever users or short-term users to never users is consistent and reassuring.

Although not entirely consistent, overall, the findings also suggest an increased risk in two important subgroups of users: users of long duration and current users. In general, users of long duration are more likely to be current users, so in many studies these two groups overlap substantially. Part of the inconsistency in findings between studies likely stems from the limited number of cases in any given study in these two groups. From a biological perspective, these are the groups one would most expect to demonstrate a relation with breast cancer risk. Exogenous estrogens are well known to increase progression of mammary tumors in animal models, and appear to act in a very late stage, perhaps stimulating growth in tumors which are already present but undiagnosed.

Although better and more complete information will be forthcoming, it is unlikely that the current controversies will be fully settled in the foreseeable future. For now, the weight of the evidence suggests little or no increase in risk among users of short duration, or of past use. However, current longer term use appears to be associated with an increased risk of breast cancer. This increase in risk is large enough, and well enough supported, to be considered along with the other risks and benefits of postmenopausal hormone therapy.

 

REFERENCES

1. Brinton LA, Schairer C, Hoover RN, Fraumeni JF. Menstral factors and risk of breast cancer. Cancer Invest 1988;6:245-254.         

2. White E. Projected changes in breast cancer incidence due to the trend toward delayed childbearing. Am J Public Health 1987;77:495-497.         

3. Trichopoulos D, MacMahon B, Cole P. Menopause and breast cancer risk. J Natl Cancer Inst 1972;48:605-613.         

4. Huang Z, Hankinson SE, Colditz GA, Stampfer MJ, Hunter DJ, Manson JE et al. Dual effects of weight and weight gain on breast cancer risk.         

5. Lilienfeld AM. The relationship of cancer of the female breast to artificial menopause and marital status. Cancer 1956;9:927-934.         

6. Feinleib M. Breast cancer and artificial menopause: A cohort study. J Natl Cancer Inst 1968;41:315-329.         

7. Rosner B, Colditz GA, Willett WC. Reproductive risk factors in a prospective study of breast cancer: The Nurses, Health Study. Am J Epidemiol 1994;139:819-835.         

8. Tretli S. Height and weight in relation to breast cancer morbidity and mortality: A prospective study of 570 000 women in Norway. Int J Cancer 1989;129:22-30.         

9. Lew EA, Garfinkel L. Variations in mortality by weight among 750 000 men and women. J Chronic Dis 1979;32:563-576.         

10. Committee on the Relationship Between Oral Contraceptives and Breast Cancer, Institute of Medicine. Oral contraceptives, breast cancer. Washington, D.C.: National Academy Press, 1991.         

11. Piper JM, Kennedy DL. Oral contraceptives in the United States: Trends in content and potency. Int J Epidemiol 1987;16:215-221.         

12. Annegers JF. Patterns of oral contraceptive use in the United States. Br J Rheumatol 1989;28 suppl 1:48-50.         

13. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives. Lancet 1996;347:1713-1727.         

14. Romieu I, Berlin JA, Colditz GA. Oral contraceptives and breast cancer: Review and meta-analysis. Cancer 1990;66:2253-2263.         

15. Thomas DB. Oral contraceptives and breast cancer: Review of epidemiologic literature. Contraception 1991;43:597-642.         

16. Meirik O, Farley TMM, Lund E, Adami HO, Christoffersen T, Bergso P. Breast cancer and oral contraceptives: Patterns of risk among parous and nulliparous women further analysis of the Swedish-Norwegian material. Contraception 1989;39:471-475.         

17. Miller DR, Rosenberg L, Kaufman DW, Stolley P, Warshauer ME, Shapiro S. Breast cancer before age 45 and oral contraceptive use: New findings. Am J Epidemiol 1989;129:269-280.         

18. UK National Case-Control Study Group. Oral contraceptive use and breast cancer risk in young women. Lancet 1989;i:973-982.         

19. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Breast cancer and combined oral contraceptives: Results from a multinational study. Br J Cancer 1990;61:110-119.         

20. Wingo PA, Lee NC, Ory HW, Beral V, Peterson HB, Rhodes P. Age-specific differences in the relationship between oral contraceptive use and breast cancer. Obstet Gynecol 1991;78:161-170.         

21. Rookus MA, Leeuwen FE., Oral Contraceptives and Breast Cancer Study Group for the Netherlands. Oral contraceptives and risk of breast cancer in women aged 20-54 years. Lancet 1994;344:844-851.         

22. Brinton LA, Daling JR, Liff JM, Schoenberg JB, Malone KE, Stanford JL et al. Oral contraceptives and breast cancer risk among younger women. J Natl Cancer Inst 1995;87:827-835.         

23. Rosenberg L, Palmer JR, Rao S, Zauber AG, Strom BL, Warshauer ME et al. Case-control study of oral contraceptive use and risk of breast cancer. Am J Epidemiol 1996;143:25-37.         

24. Vessey MP, McPherson K, Villard-Mackintosh L, Yeates D. Oral contraceptives and breast cancer: Latest findings in a large cohort study. Br J Cancer 1989;59:613-617.         

25. Kay CR, Hannaford PC. Breast cancer and the pill - a further report from the Royal College of General Practitioners’ oral contraception study. Br J Cancer 1988;58:675-680.         

26. Romieu I, Willett WC, Colditz GA, Stampfer MJ, Rosner B, Hennekens CH et al. Prospective study of oral contraceptive use and risk of breast cancer in women. J Natl Cancer Inst 1989;81:1313-1321.         

27. Hankinson SE, Colditz GA, Manson JE, Willett WC, Hunter DJ, Stampfer MJ et al. A prospective study of oral contraceptive use and risk of breast cancer. Cancer Causes Control 1997;8:65-72.         

28. Russo J, Gusterson BA, Rogers AE, Russo IH, Wellings SR, Van Zwieten MJ. Biology of disease: Comparative study of human and rat mammary tumorigenesis. Lab Invest 1990;62:244-278.         

29. White E, Malone KE, Weiss NS, Daling JR. Breast cancer among young US women in relation to oral contraceptive use. J Natl Cancer Inst 1994;86:505-514.         

30. Vessey M, Baron J, Doll R, McPherson K, Yeates D. Oral contraceptives and breast cancer: Final report of an epidemiological study. Br J Cancer 1983;47:455-462.         

31. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. Oral contraceptive use and the risk of breast cancer. N Engl J Med 1986;315:405-411.         

32. Clavel F, Andrieu N, Gairard B, Bremond A, Piana L, Lansac J et al. Oral contraceptives and breast cancer: A French case control study. Int J Epidemiol 1991;20:32-38.         

33. Ewertz M. Oral contraceptives and breast cancer risk in Denmark. Eur J Cancer 1992;28A:1176-1181.         

34. World Health Organization, Collaborative Study of Neoplasia and Steroid Contraceptives. Breast cancer and depotmedroxyprogesterone acetate: A multinational study. Lancet 1991;338:833-838.         

35. Kennedy DL, Baum C. Noncontraceptive estrogens and progestins: Use patterns over time. Obstet Gynecol 1985;65:441-446.         

36. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Int Med 1992;117:1016-1036.         

37. Newcomb PA, Longnecker MP, Storer BE, Mittendorf R, Baron J, Clapp RW et al. Long-term hormone replacement therapy and risk of breast cancer in postmenopausal women. Am J Epidemiol 1995;142:788-795.         

38. Schuurman AG, Van den Brandt PA, Goldbohm RA. Exogenous hormone use and the risk of postmenopausal breast cancer: Results from the Netherlands Cohort Study. Cancer Causes Control 1995;6:416-424.         

39. Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589-1593.         

40. Stanford JL, Thomas DB. Exogenous progestins and breast cancer. Epidemiol Rev 1993;15:98-107.         

41. Dupont WD, Page DL. Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med 1991;151:67-72.         

42. Steinberg KK, Thacker SB, Smith SJ, Stroup DF, Zack MM, Flanders WD et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991;265:1985-1990.         

43. Sillero-Arenas M, Delgado-Rodríguez M, Rodríguez-Canteras R, Bueno-Cavanillas A, Gálvez-Vargas R. Menopausal hormone replacement therapy and breast cancer: A meta-analysis. Obstet Gynecol 1992;79:286-294.         

44. Colditz GA, Egan KM, Stampfer MJ. Hormone replacement therapy and risk of breast cancer: Results from epidemiologic studies. Am J Obstet Gynecol 1993;168:1473-1480.         

45. Steinberg KK, Smith SJ, Thacker SB, Stroup DF. Breast cancer risk and duration of estrogen use: The role of study design in meta-analysis. Epidemiology 1994;5:415-421.         

46. Stanford JL, Weiss NS, Voigt LF, Daling JR, Habel LA, Rossing MA. Combined estrogen and progest in hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 1995;274:137-142.         

47. Egeland GM, Matthews KA, Kuller LH, Kelsey SF. Characteristics of noncontraceptive hormone users. Prev Med 1988;17:403-411.         

48. Schairer C, Byrne C, Keyl PM, Brinton LA, Sturgeron SR, Hoover RN. Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer (United States). Cancer Causes Control 1994;5: 491-500.         

49. Bergkvist L, Adami HO, Persson I, Hoover R, Schairer C. The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 1989;321:293-297.         

50. Brinton LA, Hoover R, Fraumeni JR Jr. Menopausal oestrogens and breast cancer risk: An expanded case-control study. Br J Cancer 1986;54: 825-832.         

51. Wingo PA, Layde PM, Lee NC, Rubin G, Ory HW. The risk of breast cancer in postmenopausal women who have used estrogen replacement therapy. JAMA 1987;257:209-215.         

52. Palmer JR, Rosenberg L, Clarke EA, Miller DR, Shapiro S. Breast cancer risk after estrogen replacement therapy: Results from the Toronto Breast Cancer Study. Am J Epidemiol 1991;134:1386-1395.         

53. Mills PK, Beeson L, Phillips RL, Fraser GE. Prospective study of exogenous hormone use and breast cancer in Seventh-day Adventists. Cancer 1989;64:591-597.         

54. Harris RE, Namboodiri KK, Wynder EL. Breast cancer risk: Effects of estrogen replacement therapy and body mass. J Natl Cancer Inst 1992;84:1575-1582.         

55. Hemminki E, Kennedy DL, Baum C, McKinlay SM. Prescribing of noncontraceptive estrogens and progestins in the United States, 1974-1986. Am J Public Health 1988;78:1479-1481.         

56. Nachtigall LE, Nachtigall RH, Nachtigall RD, Beckman EM. Estrogen replacement therapy, II: A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol 1979; 54:74-79.         

57. Gambrell RD, Maier RC, Sanders BI. Decreased incidence of breast cancer in postmenopausal estrogen-progestogen users. Obstet Gynecol 1983;62:435-445.         

58. Ewertz M. Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark. Int J Cancer 1988; 42:832-838.         

59. Kaufman DW, Miller DR, Rosenberg L, Helmrich SP, Stolley P, Schottenfeld D et al. Noncontraceptive estrogen use and the risk of breast cancer. JAMA 1984;252:63-67.         

60. Yang CP, Daling JR, Band PR, Gallagher RP, White E, Weiss NS. Noncontraceptive hormone use and risk of breast cancer. Cancer Causes Control 1992;3:475-479.         

 

 

(1) Channing Laboratory, Brigham and Women’s Hospital; Harvard Medical School, and Department of Epidemiology, Harvard School of public Health, Boston, MA, United States of America (USA).

(2) Channing Laboratoriy ; Department of Epidemiology, and Department of Nutrition, Harvard School of Public Health, and Department of Medicine, Harvard Medican School; Brigham and Women’s Hospital, USA.

 

Fecha de recibido: 10 de abril de 1997 · Fecha de aprobado: 6 de junio de 1997

Reprint to requests to: Dra. Susan E. Hankinson. Channing Laboratory, 181 Longwood Avenue, Boston, MA 02115, Unite States of America.

Instituto Nacional de Salud Pública Cuernavaca - Morelos - Mexico
E-mail: spm@insp3.insp.mx